GKSL

Gujarat Kidney And Super Speciality Limited

Gujarat Kidney And Super Speciality Limited (GKSL) financial statements and selected valuation metrics through 30 June 2026.

Healthcare›Healthcare›Healthcare Services›Hospital

gujaratsuperspecialityhospital.com

Ask AI

Key metrics

Price as of 2026-10-16

Stock price

₹187.37

Market cap

1,471 Cr

Stock P/E

92.9

P/B

5.85

ROE (FY26)

6.1%

ROCE (FY26)

8.5%

Operating margin (FY26)

27.1%

Debt / equity (FY26)

0.06

OCF / EBITDA (FY26)

-14.3%

OCF / EBITDA (3Y)

24.1%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Gujarat Kidney and Super Speciality runs a growing group of private hospitals and clinics in Gujarat, centred on its super-speciality hospital in Vadodara, and has been expanding by buying hospitals and pharmacies and, from July 2026, a clinic in Dubai.

Company snapshot

20thBy market cap

Ranked among 24 companies in Hospital.

What we see

Positives

✓Net margin of 20.5% — the business keeps a healthy share of every rupee it earns.

Concerns

✗Only 24% of operating profit came in as cash over the last three years — much of it is tied up in unpaid bills or stock.

2 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

Metric	Sept 2025	Dec 2025	Mar 2026	Jun 2026
Sales	13 Cr	23 Cr	31 Cr	34 Cr
Operating expenses (approx.)	8 Cr	16 Cr	24 Cr	26 Cr
EBITDA	5 Cr	7 Cr	6 Cr	8 Cr
OPM %	39.6%	29.7%	20.6%	24.4%
Other income	0.09 Cr	0.06 Cr	0.71 Cr	0.69 Cr
Interest	0.28 Cr	0.60 Cr	0.82 Cr	0.66 Cr
Depreciation	0.90 Cr	1 Cr	2 Cr	1 Cr
Profit before tax	4 Cr	5 Cr	5 Cr	7 Cr
Tax %	28.6%	26.3%	-3.0%	23.6%
Net profit	3 Cr	4 Cr	5 Cr	5 Cr
EPS (₹)	₹0.52	₹0.52	₹0.81	₹0.66

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	0 Cr	5 Cr	40 Cr	82 Cr	Sign in free for the trailing twelve months
Operating expenses (approx.)	0.0063 Cr	3 Cr	24 Cr	55 Cr	Sign in free for the trailing twelve months
EBITDA	—	2 Cr	17 Cr	27 Cr	Sign in free for the trailing twelve months
OPM %	—	40.9%	41.1%	32.8%	Sign in free for the trailing twelve months
Other income	0.0001 Cr	0.70 Cr	0.15 Cr	0.87 Cr	Sign in free for the trailing twelve months
Interest	—	0.07 Cr	0.65 Cr	2 Cr	Sign in free for the trailing twelve months
Depreciation	—	0.32 Cr	3 Cr	5 Cr	Sign in free for the trailing twelve months
Profit before tax	-0.0062 Cr	2 Cr	13 Cr	21 Cr	Sign in free for the trailing twelve months
Tax %	—	24.4%	25.6%	20.8%	Sign in free for the trailing twelve months
Net profit	-0.0062 Cr	2 Cr	9 Cr	17 Cr	Sign in free for the trailing twelve months
EPS (₹)	—	₹0.49	₹1.85	₹2.49	Sign in free for the trailing twelve months
Dividend payout %	—	—	—	0.0%	Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	0.20 Cr	0.20 Cr	11 Cr	16 Cr
Reserves	0.17 Cr	11 Cr	15 Cr	237 Cr
Borrowings	—	2 Cr	4 Cr	16 Cr
Other liabilities	3 Cr	8 Cr	24 Cr	27 Cr
Total liabilities	4 Cr	21 Cr	55 Cr	298 Cr
Fixed assets (net)	—	10 Cr	20 Cr	27 Cr
CWIP	—	—	—	—
Investments	—	—	—	0 Cr
Loans & advances	—	—	—	0.85 Cr
Inventories	—	0.27 Cr	0.68 Cr	2 Cr
Trade receivables	1 Cr	4 Cr	15 Cr	39 Cr
Cash & bank	0.0035 Cr	0.97 Cr	3 Cr	13 Cr
Other assets	3 Cr	5 Cr	17 Cr	216 Cr
Total assets	4 Cr	21 Cr	55 Cr	298 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	0.0001 Cr	1 Cr	14 Cr	-4 Cr
Cash from investing	0 Cr	0.22 Cr	-18 Cr	-214 Cr
Cash from financing	0 Cr	-0.47 Cr	6 Cr	228 Cr
Net cash flow	0.0001 Cr	0.97 Cr	2 Cr	11 Cr
Free cash flow (OCF − Capex)	—	—	2 Cr	-98 Cr

Ratios

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROCE %	-1.7%	18.3%	43.3%	8.5%
ROE %	-1.7%	15.9%	34.7%	6.1%
Debtor days	—	321	137	171
Inventory days	—	321	62	82
Days payable	—	2610	298	338
Cash conversion cycle	—	-1967	-99	-84
OCF / EBITDA %	—	62.2%	82.2%	-14.3%
OCF / EBITDA % (3 years)	—	—	—	24.1%
Debt / equity	—	0.18	0.15	0.06
Current ratio	0.33	1.59	1.01	3.76
Net debt / EBITDA	—	0.50	0.08	0.09